
繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
iBio Inc | 10-Q: Q2 2024 Earnings Report
iBio Inc | 10-Q: Q2 2024 Earnings Report
iBio Inc | 10-Q:2024財年二季報
牛牛AI助理已提取核心訊息
iBio Inc, a biotechnology company specializing in AI-driven biologics, has not reported any revenue for the third quarter of Fiscal 2024. The company's financial performance shows a net loss from continuing operations of approximately $4.5 million, or $2.42 per share, for the quarter ended December 31, 2023. This is a decrease from the net loss of approximately $10.6 million, or $21.54 per share, for the same period in the previous year. Research and Development (R&D) expenses decreased by approximately $1.3 million, primarily due to in-house task performance and reduced spending on consultants. General and Administrative (G&A) expenses also decreased by approximately $4.8 million, mainly due to reduced personnel costs and lower consultancy expenses. The company's total operating expenses for the quarter were approximately...Show More
iBio Inc, a biotechnology company specializing in AI-driven biologics, has not reported any revenue for the third quarter of Fiscal 2024. The company's financial performance shows a net loss from continuing operations of approximately $4.5 million, or $2.42 per share, for the quarter ended December 31, 2023. This is a decrease from the net loss of approximately $10.6 million, or $21.54 per share, for the same period in the previous year. Research and Development (R&D) expenses decreased by approximately $1.3 million, primarily due to in-house task performance and reduced spending on consultants. General and Administrative (G&A) expenses also decreased by approximately $4.8 million, mainly due to reduced personnel costs and lower consultancy expenses. The company's total operating expenses for the quarter were approximately $4.5 million, compared to $10.6 million in the previous fiscal year. iBio Inc has also reported losses from discontinued operations, including an impairment of fixed assets and costs to maintain the Facility. The company's liquidity and capital resources are a concern, with a history of significant losses and negative cash flows from operations. iBio Inc's management has acknowledged substantial doubt about the company's ability to continue as a going concern without additional financing. In terms of business development, iBio Inc is focused on leveraging its AI Discovery Platform for partnerships and licensing in diverse therapeutic areas, with a particular emphasis on oncology. The company has entered into collaborations with the National Institute of Allergy and Infectious Diseases (NIAID) and a large pharmaceutical company to utilize its AI-driven epitope steering platform. iBio Inc's future plans include advancing its proprietary platform, epitope steering technology, and progressing internal pre-clinical programs, with a strategic focus on oncology and immunology. The company is also exploring the sale of its CDMO business and Facility to improve liquidity.
生物技術公司iBio Inc專注於以人工智能驅動的生物製品,截至2023年12月31日的第三財季公司未報告任何營業收入。公司財務業績顯示,截至2023年12月31日的本季度持續經營業務淨損失約450萬美元,每股淨損失2.42美元,相較上年同期淨損失約1060萬美元,每股淨損失21.54美元有所下降。研發(R&D)費用約降低了130萬美元,主要是因爲內部任務執行和顧問支出減少的原因。總公司及行政(G&A)費用也下降了約480萬美元,主要是由於人員成本減少和顧問費用降低。本季度公司的總營業費用約爲450萬美元,而上一財年爲1060萬美元。iBio Inc也報告了來自終止業務的虧損,包括固定資產減值...展開全部
生物技術公司iBio Inc專注於以人工智能驅動的生物製品,截至2023年12月31日的第三財季公司未報告任何營業收入。公司財務業績顯示,截至2023年12月31日的本季度持續經營業務淨損失約450萬美元,每股淨損失2.42美元,相較上年同期淨損失約1060萬美元,每股淨損失21.54美元有所下降。研發(R&D)費用約降低了130萬美元,主要是因爲內部任務執行和顧問支出減少的原因。總公司及行政(G&A)費用也下降了約480萬美元,主要是由於人員成本減少和顧問費用降低。本季度公司的總營業費用約爲450萬美元,而上一財年爲1060萬美元。iBio Inc也報告了來自終止業務的虧損,包括固定資產減值和維持設施的費用。公司的流動性和資本資源是一個問題,有着重大虧損和經營活動現金流爲負的歷史。iBio Inc的管理層已經承認公司需要額外融資才能繼續作爲一個經營實體存在的重大疑慮。在業務發展方面,iBio Inc專注於利用其AI發現平台,在各種治療領域建立合作伙伴關係和許可,尤其是在腫瘤領域。公司與美國國家過敏和傳染病研究所(NIAID)和一家大型製藥公司合作利用其AI驅動的表位導向平台。iBio Inc的未來計劃包括推進其專有平台、表位導向技術以及內部臨床前項目,戰略重點放在腫瘤和免疫學領域。公司還在考慮出售其CDMO業務和設施以改善流動性。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
投資課程

看財報揀好股
快速掌握財報季學習指引
財報季來臨,公司股價最易大升大跌,很多優秀的投資者會將財報季視為“大賺一筆”的好時機。 假設你現在持有某隻股票,該公司發佈財報後股價跳水,大跌10%,此時你會怎麼做? 短期波動不改長期增長邏輯,堅定持有 財報業績不及預期,馬上賣掉止盈止損 未來可能還要跌,賣掉之後反手做空 具體如何選擇?取決於我們是什麼類型的投資者,也
【2025.1】特斯拉業績怎麽看?關註這四個重點
又到了美股業績期。而巨頭公司的業績,不但會影響自己的股價,甚至還會影響整個美股市場的走勢,其中也可能蘊含著交易機會。 那麼,這些巨頭公司的業績該怎麼看呢?今天我們聚焦特斯拉,看看特斯拉的業績有哪些關鍵因素,可能會對股價帶來什麼明顯影響…… 1、銷量變化 首先,對新能源車企來說,最重要的觀察指標始終是總交付量, 或者說銷
【2024.11】60年上漲超4萬倍,成就股神巴菲特之名!伯克希爾的業績怎麼看?
要說到投資界的傳奇人物, $伯克希尔-B (BRK.B.US)$ 的掌舵者沃倫.巴菲特,一定是一個繞不開的名字。伯克希爾在1965-2023年期間高達4.38萬倍的回報,也成就了巴菲特的股神之名。伯克希爾公司的一些重大動作,也牽動着資本市場的神經,成爲市場風向標之一。 伯克希爾每次業績的發佈,自然也成爲市場關注的重中之